


## ASBMB@UCSB PRESENTS BIOTECH TALK • VASCULAR BIOSCIENCES Providing Targeted Solutions for Serious Diseases


Vascular BioSciences (VBS) is a <u>biopharmaceutical</u> and <u>medical device</u> company focused on developing solutions for difficult-to-treat cardiovascular and inflammatory diseases – the leading cause of serious illness and death in industrialized countries. VBS aims to discover the intrinsic causes and mechanisms of disease in order to lay the foundation for a robust array of next generation targeted pharmaceuticals, interventional devices and personalized molecular diagnostics.



Their lead therapeutic candidate, <u>CAR peptide</u>, represents a new paradigm in targeted therapy. Additionally, their efforts to find better solutions for treating vascular-based diseases has resulted in the world's first and only method of endoarterial biopsy sampling that does not require invasive surgery.

David Mann, CEO & Chairman of VBS, is the inventor of the endoarterial biopsy catheter and co-discoverer of CAR peptide's utility for pulmonary hypertension, sepsis and other diseases. Mr. Mann has been awarded over 30 patents, is an author of 18 scientific publications, and has been awarded 10 highly competitive federal and state <u>research grants</u> as the Principal or Co-Principal Investigator.

Join us to learn more about current research and opportunities at VBS! Refreshments will be provided.



MONDAY FEB 24, 2020 5PM - PSBN 4606

asbmbucsbchapter.github.io • vascularbiosciences.com